Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Nucor logoNucor NUE

The company said it filed Amendment No. 1 to amend the Original 8-K it filed on February 20, 2026, which concerned the election of John L. "Jack" Sullivan as Chief Financial Officer, Treasurer and Executive Vice President, effective March 1, 2026.

8-K/ADeparture or Appointment of Directors or Certain Officers (amended)Amended filingFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said it filed Amendment No. 1 to amend the Original 8-K it filed on February 20, 2026, which concerned the election of John L. "Jack" Sullivan as Chief Financial Officer, Treasurer and Executive Vice President, effective March 1, 2026.

  2. Nucor said it entered into an Executive Employment Agreement with Sullivan on February 26, 2026, and that his annual base salary will increase to $680,000 effective March 1, 2026. The agreement supersedes prior employment-related agreements, including his Executive Agreement dated as of December 20, 2024.

  3. The company said the non-compete benefit equals 1 month(s) of base salary for each 1 year(s) of service, subject to a minimum of 6 month(s) of base salary, and that if Sullivan is under age 55 at termination, the benefit will be no less than the value of his forfeitable deferred common stock units and restricted stock awarded under the long-term incentive plan. The benefit will be paid in 24 equal monthly installments following termination. It said no non-compete benefit is payable if Sullivan dies while employed by the company.

  4. The company said that if Sullivan's employment is involuntarily terminated by Nucor or he resigns for Good Reason within 24 months of a change in control, he would receive a lump-sum non-compete benefit. The benefit equals 2.5 times a "base amount" plus the value of restricted stock units that would have been granted in the year of termination. Medical, dental and prescription drug coverage would continue for 30 months.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Amended filing overview and effective date of CFO appointment

The company said it filed Amendment No. 1 to amend the Original 8-K it filed on February 20, 2026, which concerned the election of John L. "Jack" Sullivan as Chief Financial Officer, Treasurer and Executive Vice President, effective March 1, 2026.

Source · Based on the filing body and exhibits

Executive Employment Agreement and Base Salary Increase

Nucor said it entered into an Executive Employment Agreement with Sullivan on February 26, 2026, and that his annual base salary will increase to $680,000 effective March 1, 2026. The agreement supersedes prior employment-related agreements, including his Executive Agreement dated as of December 20, 2024.

Source · Based on the filing body and exhibits

Non-Compete Benefit Terms Upon Termination

The company said the non-compete benefit equals 1 month(s) of base salary for each 1 year(s) of service, subject to a minimum of 6 month(s) of base salary, and that if Sullivan is under age 55 at termination, the benefit will be no less than the value of his forfeitable deferred common stock units and restricted stock awarded under the long-term incentive plan. The benefit will be paid in 24 equal monthly installments following termination. It said no non-compete benefit is payable if Sullivan dies while employed by the company.

Source · Based on the filing body and exhibits

Replacement Benefits After Change in Control Termination

The company said that if Sullivan's employment is involuntarily terminated by Nucor or he resigns for Good Reason within 24 months of a change in control, he would receive a lump-sum non-compete benefit. The benefit equals 2.5 times a "base amount" plus the value of restricted stock units that would have been granted in the year of termination. Medical, dental and prescription drug coverage would continue for 30 months.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.